VALEDIA®

VALBIOTIS announces positive results from the Phase IIA clinical study of VALEDIA®.

TOTUM-63

VALBIOTIS to present novel data about TOTUM-63 and metabolic diseases prevention at the 2019 scientific sessions of the American Diabetes Association.

VALEDIA®

VALBIOTIS succeeds in the industrial production of VALEDIA®, a major scientific innovation for prediabetic people, in collaboration with the Pierre Fabre group.

VALEDIA®

VALBIOTIS obtains the European patent for VALEDIA®.

VALEDIA®

A major scientific innovation for people with prediabetes.

Prediabetes

VALBIOTIS publishes the first prediabetes market data.